# G6PD Inhibition ### Overview of G6PD Inhibition: Pentose Phosphate Pathway Disruption by Polydatin Polydatin directly inhibits glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway (PPP). This has been confirmed in enzyme activity assays on cancer cell lysates and on purified G6PD protein, **making polydatin one of the first naturally derived compounds shown to directly block this enzyme**. The downstream consequences of this block are meaningful across several cancer biology mechanisms: * Reduced NADPH production, limiting cancer cells' ability to neutralise reactive oxygen species (ROS) * Impaired nucleotide synthesis disrupts DNA replication in rapidly dividing cells * Redox imbalance, triggering ROS-mediated endoplasmic reticulum (ER) stress, cell cycle arrest at S phase, and apoptosis * Inhibition of invasion and metastasis — in an orthotopic oral cancer model, 100 mg/kg polydatin reduced tumour size by approximately 30% and inhibited lymph node metastases by approximately 80% The vulnerability of any given cancer to this mechanism depends heavily on its reliance on PPP flux for survival, biosynthesis, and redox protection.
### *Understanding the Pentose Phosphate Pathway in Cancer Cells: A Metabolic Perspective* Expand using the arrow to read
Understanding the Pentose Phosphate Pathway in Cancer Cells: A Metabolic Perspective Cancer cells are metabolically flexible in ways that healthy cells are not. Where a normal cell relies primarily on mitochondrial oxidative phosphorylation to generate energy efficiently, cancer cells rewire their metabolism to prioritise speed and biosynthesis over efficiency — running high volumes of glucose through glycolysis even in the presence of oxygen, a phenomenon known as the Warburg effect.\ \ The pentose phosphate pathway (PPP) branches directly off this glycolytic highway at the very first step, diverting glucose-6-phosphate away from energy production and toward the raw materials cancer cells need to proliferate rapidly: ribose-5-phosphate for nucleotide and DNA synthesis, and NADPH for antioxidant defence and lipid biosynthesis. This creates an important but underappreciated vulnerability — when the PPP is inhibited, cancer cells do not simply lose one pathway in isolation.\ \ Because these pathways are deeply interconnected, disrupting PPP flux exerts pressure on the entire metabolic network: NADPH levels fall, oxidative stress rises, nucleotide supply for DNA replication declines, and the cancer cell's ability to synthesise the lipids it needs for rapid membrane production is compromised.\ \ What makes this more complex — and more clinically interesting — is that metabolically flexible cancers can partially compensate by upregulating alternative carbon sources, such as glutamine (via glutaminolysis) or fatty acid oxidation, when glucose-dependent pathways are under pressure.\ \ This metabolic rerouting is one reason why single-pathway interventions rarely achieve durable results on their own. Polydatin addresses this by acting across several of these interconnected nodes simultaneously — inhibiting G6PD at the PPP entry point, modulating NF-κB and mTOR signalling that drive metabolic reprogramming upstream, and generating ROS-mediated stress that overwhelms the very antioxidant capacity the cancer cell was relying on the PPP to maintain.\ \ Used alongside dietary strategies that reduce glucose and insulin availability — such as therapeutic ketosis or intermittent fasting — polydatin's enzymatic interference compounds the metabolic pressure on cancer cells from multiple directions at once, while healthy cells with lower biosynthetic demands and intact mitochondrial function are far less dependent on these same pathways for survival.
*** ### Why Some Cancers Are More PPP-Dependent Than Others Not all cancers use the PPP equally. Tumours that are highly proliferative, face elevated internal oxidative stress, or rely on Warburg-type glycolysis tend to upregulate G6PD activity as a survival mechanism. In these cancers, the PPP becomes a critical pathway — not just for nucleotide production, but for maintaining the NADPH they need to protect themselves against their own ROS burden and against the oxidative damage caused by chemotherapy. Pan-cancer transcriptomic analysis of TCGA data (covering 33 tumour types) confirmed that G6PD is upregulated in most cancers compared to adjacent normal tissues. **Higher G6PD expression correlated with worse overall survival, disease-specific survival, and progression-free interval across multiple cancer types** — and drug sensitivity analysis showed that IC50 values for most anti-cancer agents were positively correlated with G6PD expression levels, suggesting G6PD-high tumours are not only more aggressive but also more chemoresistant.
*** ## Cancer Types Showing Particular G6PD-Dependent Vulnerability Source titles and URL's follow at the bottom of this page ### Oral and Head and Neck Cancers (HNSC) The direct G6PD-inhibiting effect of polydatin was first characterised in an oral/tongue cancer model. Polydatin inhibited cell proliferation, induced approximately 50% apoptosis, and reduced invasion by approximately 60% in vitro. In vivo, lymph node metastases were reduced by approximately 80%. This is currently the most mechanistically detailed cancer model for polydatin's PPP-disrupting effect. Pan-cancer survival analysis confirms that higher G6PD expression correlates with worse outcomes in head and neck squamous cell carcinoma. *** ### Clear Cell Renal Cell Carcinoma (ccRCC / KIRC) G6PD is markedly overexpressed in ccRCC, and its expression increases in a stepwise fashion from Fuhrman grade 1 through to grade 4. In a study of 149 ccRCC patients, high G6PD expression was significantly associated with tumour extent, lymph node metastasis, Fuhrman grade, and TNM stage. Patients with high G6PD expression had a median survival of approximately 1,110 days, substantially shorter than that of patients with low G6PD expression. Cox regression confirmed high G6PD as an independent prognostic factor for poor overall survival. TCGA-wide pan-cancer analysis consistently places KIRC among the cancers most strongly associated with G6PD-driven worse prognosis. *** ### Hepatocellular Carcinoma (LIHC / HCC) G6PD is highly expressed in HCC tissues, and its expression correlates positively with tumour status, vascular invasion, histologic grade, and TNM-T stage. A survival analysis of 77 HCC patients from Sun Yat-sen University confirmed that those with high G6PD expression had shorter overall survival. In HCC, G6PD-mediated PPP activation appears to be one mechanism by which cancer cells resist oxidative damage induced by chemotherapy agents such as oxaliplatin. G6PD inhibition may increase the sensitivity of liver cancer cells to treatment. *** ### Acute Myeloid Leukaemia (AML / LAML) AML is among the cancers for which pan-cancer Cox regression specifically identifies high G6PD expression as a risk factor for worse outcomes. Preclinical research shows that G6PD suppression in AML cells abolishes glycolysis, weakens PPP activity, decreases glucose utilisation, and leads to growth arrest or cell death. AML cells with G6PD inhibition also become more sensitive to chemotherapeutic drugs, suggesting G6PD is a driver of both proliferation and treatment resistance in this context. *** ### Bladder Cancer (BLCA) G6PD expression is upregulated in bladder cancer tissues compared to adjacent normal tissue, and expression levels increase with rising tumour T stage (suggesting the cancer was ramping up PPP activity as it became more aggressive). Patients with higher G6PD expression clearly have worse overall and disease-free survival. Knockdown of G6PD in bladder cancer cell lines raises intracellular ROS to toxic levels, reduces colony formation, and suppresses AKT signalling — a pathway also linked to tumour progression in this cancer type. *** ### Breast Cancer In primary breast carcinoma, G6PD overexpression was found to be an independent prognostic factor for progression-free survival (PFS). Patients whose tumours expressed high G6PD had a mean PFS of approximately 32 months, compared to approximately 71 months in those with low G6PD expression. G6PD-high primary tumours were more likely to develop recurrent metastasis during follow-up. Pan-cancer survival data also place BRCA among cancers where high G6PD predicts worse overall outcomes. *** ### Lower-Grade Glioma (LGG) G6PD is among the most strongly prognostic markers in lower-grade glioma in pan-cancer TCGA analysis, with high G6PD levels associated with significantly shorter overall survival, disease-specific survival, and progression-free interval. Pan-cancer Cox regression specifically identifies LGG as a cancer where G6PD elevation represents an independent risk factor for worse outcomes. *** ### Mesothelioma (MESO) Mesothelioma is consistently identified across pan-cancer analyses as a tumour type in which high G6PD expression correlates with worse overall survival and shorter progression-free interval. MESO appears in the highest-risk group for G6PD-driven prognosis in Cox regression modelling across 33 TCGA cancer types. *** ### Lung Cancer G6PD expression in lung cancer correlates with disease stage and other adverse clinical features. Preclinical data show that G6PD inhibition in lung cancer cells raises ROS, suppresses proliferation, and induces apoptosis. *** ### Prostate Cancer (PRAD) G6PD and PPP activity in prostate cancer is regulated in part through an androgen receptor–mTOR axis. High G6PD expression is associated with worse progression-free interval in prostate cancer, and G6PD inhibition suppresses androgen-responsive tumour growth in preclinical models. *** ### Cervical Cancer Elevated G6PD expression in cervical carcinoma has been associated with high-risk HPV infection events, suggesting G6PD upregulation may be part of virus-driven oncogenic reprogramming of glucose metabolism in this cancer type. *** ### Ovarian Cancer G6PD and PPP activity have been linked to ovarian cancer metastasis via exosome-mediated signalling. G6PD inhibition has been shown to sensitise ovarian cancer cells to oxidative stress. *** ### Gastric Cancer Overexpression of G6PD in gastric cancer is associated with poor clinical outcomes. The pattern of G6PD upregulation in gastric cancer parallels findings in renal and breast cancers, where it is linked to advanced stage and aggressive behaviour. *** ### **What is Cox Regression?** Expand using the arrow to read
Cox Regression in a Nutshell: Cox Regression is mentioned repeatedly across cancer types (above), so in a nutshell, Cox regression (also called Cox proportional hazards modelling) is a statistical method used in cancer research to **measure the relationship between a biological feature** — such as G6PD expression level — **and patient survival outcomes.**\ \ It is considered a robust tool because it can account for multiple variables simultaneously (for example, age, tumour stage, and G6PD expression), allowing researchers to determine whether G6PD expression independently predicts worse survival or is simply tagging along with another known risk factor, such as advanced stage.\ \ When a study says G6PD is an "independent prognostic factor" confirmed by Cox regression, it means the survival disadvantage associated with high G6PD remained significant even after accounting for all other variables in the model.\ \ The larger the dataset — in this case, TCGA data spanning 33 cancer types — the more reliable the Cox regression result tends to be.
*** ### Shared Features of G6PD-Vulnerable Cancer Subtypes Across these cancers, the following features tend to mark tumours that are most likely to be vulnerable to G6PD/PPP disruption by polydatin: * High intrinsic G6PD expression or activity, confirmed by tissue analysis or TCGA data * Strong Warburg phenotype with elevated glucose uptake and high biosynthetic demand * Elevated baseline ROS, creating heavy reliance on NADPH for redox protection * PPP-linked chemotherapy resistance, where G6PD suppression restores drug sensitivity * Advanced stage or aggressive subtype — G6PD elevation frequently tracks with higher grade, lymph node involvement, and worse survival It is important to note that while the pan-cancer data and preclinical models are compelling, most of this evidence comes from cell lines, animal models, and genomic association studies. Large clinical trials specifically targeting G6PD in these cancers — or using polydatin for this mechanism — remain limited. This mechanism should be understood as a well-supported biological rationale for ongoing investigation, not as confirmed clinical proof of benefit in any specific cancer. ### Combining Polydatin with Dietary Changes **Q: If someone is using a therapeutic diet as part of their cancer approach, would that diet already be inhibiting G6PD or reducing PPP activity?** The short answer is — yes, partially, and through several overlapping mechanisms. But it is unlikely to be sufficient on its own to fully suppress G6PD in an aggressive tumour, which is why compounds like polydatin that directly inhibit the enzyme remain of interest even in people already eating therapeutically ketogenic. **How a carefully crafted ketogenic diet may reduce PPP activity:** * The PPP runs on glucose-6-phosphate, which is generated directly from dietary glucose. A ketogenic diet sharply reduces circulating glucose and insulin, meaning less glucose-6-phosphate is available as raw material for G6PD to act on — so PPP flux is reduced by substrate limitation, even if G6PD enzyme levels themselves remain unchanged * Low insulin and low blood glucose also reduce the activity of upstream glycolytic enzymes, further limiting the feed into the PPP * Ketosis reduces mTORC1 signalling, and mTORC1 is one of the key upstream drivers of G6PD expression and PPP upregulation in cancer cells — so keto may modestly reduce G6PD gene expression over time as well * Beta-hydroxybutyrate (the primary ketone body) has been shown to inhibit HDAC enzymes and alter metabolic gene expression in cancer cells in ways that may include some downregulation of PPP-related genes **Where the limitation lies:** * Many aggressive cancers with high G6PD expression can upregulate the PPP using glutamine or other non-glucose carbon sources, partially compensating for reduced glucose availability — this is especially documented in KRAS-mutant cancers (colorectal, pancreatic, lung) and in some breast cancer subtypes * G6PD protein expression — the amount of the enzyme present — is driven by oncogenes such as mutant p53, NRF2, HIF-1α, and the PI3K/AKT pathway. These drivers do not fully switch off with dietary glucose restriction alone **The combined picture:**\ A therapeutic ketogenic diet and polydatin may work complementarily. Keto reduces the substrate supply to the PPP and modestly dampens upstream signalling drivers of G6PD. Polydatin then directly inhibits the G6PD enzyme itself, adding a second layer of PPP suppression that does not depend purely on glucose restriction. This kind of metabolic stacking — reducing fuel availability while also targeting the enzyme — is a rationale some integrative oncologists find logical, though formal clinical trials combining keto with polydatin have not yet been conducted. **Bottom line:**\ Someone already on a therapeutic ketogenic diet is likely already reducing their PPP activity to some degree — and that is a meaningful metabolic advantage. Adding polydatin may deepen that PPP suppression at the enzyme level, rather than just at the substrate supply level. This is a reasonable hypothesis supported by the biology and worth discussing with their treating integrative oncology clinician. *** ### References for G6PD Inhibition and PPP Disruption A new inhibitor of glucose-6-phosphate dehydrogenase blocks the pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo\ Pan-cancer analysis reveals that G6PD is a prognostic biomarker and is correlated with immune infiltration in multiple cancers\ Overexpression of G6PD Represents a Potential Prognostic Factor in Clear Cell Renal Cell Carcinoma\ Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma\ Modulation of G6PD affects bladder cancer via ROS accumulation and AKT pathway suppression\ Exploring the role of glucose-6-phosphate dehydrogenase in cancer\ The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer\ G6PD inhibition sensitises ovarian cancer cells to oxidative stress in the ascites microenvironment\ ###

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/anticancer-mechanisms/g6pd-inhibition.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.